4.7 Article

Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 34, Issue 7, Pages 1673-1684

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2008.225

Keywords

prefrontal cortex; schizophrenia; phencyclidine; prepulse inhibition; baclofen; GABA-B

Funding

  1. Adlerbertska Forskningsstiftelsen, AstraZeneca, Sweden
  2. Swedish Medical Research Council [4247]
  3. Wilhelm och Martina Lundgrens Vetenskapsfond
  4. Hjarnfonden
  5. Jubileumsfonden
  6. Konrad och Helfrid Johanssons fond
  7. Lundbeck Foundation
  8. Royal Society of Chemistry (Analytical Division)
  9. Schizofrenisallskapet
  10. Stiftelsen Goljes Minne
  11. Stiftelsen Tornspiran
  12. Svenska Lakarsallskapet (the Swedish Society of Medicine)
  13. Svenska Sallskapet for Medicinsk Forskning (the Swedish Society for Medical Research)
  14. Ahlen-stiftelsen
  15. Ake Wibergs Stiftelse

Ask authors/readers for more resources

Recent theories propose that both GABA and glutamate signaling are compromised in patients with schizophrenia. These deficits can be observed in several brain regions including the prefrontal cortex (PFC), an area extensively linked to the cognitive dysfunction in this disease and notably affected by NMDA receptor antagonists such as phencyclidine (PCP). We have previously demonstrated that inhibition of the nitric oxide (NO) pathways in the brain, particularly in the PFC, prevents a wide range of PCP-induced behavioral deficits including disruption of prepulse inhibition (PPI). This study investigated the role of GABA(B) receptor signaling and NO in the effects of CP on PPI. Mice received systemic or prefrontal injections of the GABA(B) receptor agonist baclofen (2.5-5 mg/kg and 1 mM) before PCP treatment (5 mg/kg) and were thereafter tested for PPI. GABA/NO interactions were studied by combining baclofen and the NO synthase inhibitor L-NAME (20 mg/kg) in subthreshold doses. The role of GABA(B) receptors for NO production in vivo was assessed using NO-sensors implanted into the rat PFC. PCP-induced PPI deficits were attenuated in an additive manner by systemic baclofen treatment, whereas prefrontal microinjections of baclofen completely blocked the effects of PCP, without affecting PPI per se. The combination of baclofen and L-NAME was more effective in preventing the effects of PCP than any compound by itself. Additionally, baclofen decreased NO release in the PFC in a dose-related manner. This study proposes a role for GABA(B) receptor signaling in the effects of PCP, with altered NO levels as a downstream consequence. Thus, prefrontal NO signaling mirrors an altered level of cortical inhibition that may be of importance for information processing deficits in schizophrenia. Neuropsychopharmacology (2009) 34, 1673 -1684; doi: 10.1038/npp.2008.225; published online 14 January 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available